retatrutide triple hormone receptor agonist mechanism of action Dual and Gut Peptide Agonists on the Horizon for the Treatment Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Retatrutide — The Most Advanced

By the 16th week, compared with other treatment groups, the MNs/GLP-1RAs@NPs-WYRGRL group showed the most significant improvement in the clinical scores and thickness of the hind paws compared with the RA group with statistically significant difference

12 Based on current cardiovascular outcome data such as that provided in SUSTAIN-6, the American Diabetes Association (ADA) now recommends GLP-1 receptor agonists with proven cardiovascular benefit as a preferred option for second-line add-on therapy in patients with T2DM and established atherosclerotic cardiovascular disease (ASCVD) following metformin and lifestyle-change intensification

What outcomes do you claim, and what is the evidence

In most cases, there is no reason to discontinue GLP-1 treatment unless another specific medical indication arises